Medications For Heart Failure Market Report 2026

Medications For Heart Failure Market Overview

• Medications For Heart Failure market size has reached to $10.79 billion in 2025 • Expected to grow to $15.03 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: The Rising Prevalence Of Cardiovascular Diseases Fueling The Growth Of The Market Due To Increasing Demand For Effective Heart Failure Treatments • Market Trend: Advancements In Sodium-Glucose Cotransporter (SGLT) Inhibitors For Heart Failure Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Medications For Heart Failure Market?

Medications for heart failure are drugs used to treat and manage heart failure, a condition in which the heart cannot pump blood effectively to meet the body's needs. These medications help improve heart function, relieve symptoms, prevent hospitalizations, and increase survival. The main types of drug classes of medications for heart failure are angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, aldosterone antagonists, angiotensin II receptor blockers (ARBs), and others. ACE inhibitors relax blood vessels by blocking the formation of angiotensin II, lowering blood pressure, and reducing the heart's workload, and are commonly used for high blood pressure and heart failure. It is administered through different routes of administration, such as oral, intravenous, and others, and distributed through various distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others, for several applications, such as hospitals, clinics, and others.

What Is The Medications For Heart Failure Market Growth Forecast?

The medications for heart failure market size is expected to see strong growth in the next few years. It will grow to $15.03 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growth in heart failure patient population, increasing adoption of novel drug classes, rising focus on personalized cardiovascular therapy, expansion of outpatient and home-based care models, stronger emphasis on preventive cardiology. Major trends in the forecast period include rising adoption of combination drug therapies, growing use of SGLT2 inhibitors in heart failure treatment, increasing focus on early diagnosis and long-term disease management, expansion of evidence-based treatment guidelines, higher emphasis on reducing heart failure hospitalizations.

Global Medications For Heart Failure Market Segmentation

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Beta Blockers, Diuretics, Aldosterone Antagonists, Angiotensin II Receptor Blockers (ARBs), Other Drug Classes 2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administrations 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels 4) By Application: Hospital, Clinic, Other Applications Subsegments: 1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril, Captopril, Perindopril 2) By Beta Blockers: Carvedilol, Metoprolol Succinate, Bisoprolol, Nebivolol 3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics 4) By Aldosterone Antagonists: Spironolactone, Eplerenone 5) By Angiotensin II Receptor Blockers (ARBs): Valsartan, Losartan, Candesartan, Irbesartan 6) By Other Drug Classes: Angiotensin Receptor-Neprilysin Inhibitors, Ivabradine, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Hydralazine Or Isosorbide Dinitrate, Digoxin

What Is The Driver Of The Medications For Heart Failure Market?

The rising prevalence of cardiovascular diseases is expected to propel the growth of the medications for the heart failure market going forward. Cardiovascular diseases refer to conditions that impact the heart and blood vessels, commonly resulting in severe issues such as heart attacks and strokes. The rise in cardiovascular diseases is largely driven by sedentary lifestyles that weaken heart and vessel health over time. As cardiovascular disease rates rise, the demand for effective treatments grows, prompting greater investment in heart failure medications. With the condition becoming more widespread, pharmaceutical companies are prioritizing the development and enhancement of therapies to better manage symptoms and improve patient outcomes. For instance, in September 2024, according to the Heart Failure Society of America (HFSA), a US-based organization of heart failure experts, around 6.7 million Americans aged 20 and older currently live with heart failure (HF), with the number projected to increase to 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. Therefore, the rising prevalence of cardiovascular diseases is driving the growth of medications for the heart failure market.

Key Players In The Global Medications For Heart Failure Market

Major companies operating in the medications for heart failure market are Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol‑Myers Squibb, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals Inc., CSPC Pharmaceutical, Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals, Ionis Pharmaceuticals Inc., Hainan Poly Pharm Co Ltd, Lunan Pharmaceutical Group, Mylan Laboratories Inc., JM Laboratories, Lexicon Pharmaceuticals, Pfizer Inc, Johnson & Johnson, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Amgen Inc, Otsuka Pharmaceutical Co Ltd

Global Medications For Heart Failure Market Trends and Insights

Major companies operating in the medication for heart failure market are focused on developing advanced drugs, such as sodium-glucose cotransporter (SGLT) inhibitors, to provide more effective long-term management of heart failure symptoms and complications. An SGLT inhibitor is an advanced medication that targets glucose reabsorption mechanisms to manage heart failure, enhance efficiency, and optimize cardiovascular health. For instance, in May 2023, Lexicon Pharmaceuticals, a US-based biopharmaceutical company, introduced Inpefa (sotagliflozin), which received approval from the Food and Drug Administration (FDA). It is a once-daily oral tablet designed to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. This approval marks a significant milestone for Lexicon, as Inpefa is the first dual SGLT1/SGLT2 inhibitor to reach the market, offering a new treatment option for heart failure patients across a broad range of conditions.

What Are Latest Mergers And Acquisitions In The Medications For Heart Failure Market?

In March 2024, Novo Nordisk, a Denmark-based pharmaceutical company, acquired Cardior Pharmaceuticals for $1.112 billion. The acquisition aims to strengthen Novo Nordisk's pipeline in cardiovascular disease, particularly with Cardior's lead compound CDR132L, which is in phase 2 clinical development for treating heart failure. Cardior Pharmaceuticals is a Germany-based biotechnology company that is involved in the research of oligonucleotide-based inhibitors designed for heart failure.

Regional Outlook

North America was the largest region in the medications for the heart failure market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Medications For Heart Failure Market?

The medications for the heart failure market consist of sales of angiotensin receptor-neprilysin inhibitors, hydralazine and nitrates, ivabradine, and digoxin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Medications For Heart Failure Market Report 2026?

The medications for heart failure market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the medications for heart failure industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.